BioAsset

Insights / All articles

Research

Blackstone x TPG Make Hologic Private ($18.3B)

By Dmitry Vysotskiy, Founder & President at BioAsset · 4 slides

Blackstone and TPG have announced that they will buy out all outstanding shares of Hologic and take the women’s health company private, in a deal valued at up to $18.3 billion. The offer is $76 per share in cash plus up to $3 per share in contingent value rights, or as much as $79 per share. That is a 46% premium, the extra amount the buyers are offering above what the market valued the shares at.

The deal

A take-private deal means Hologic is being made into a private company. The buyers are both American alternative asset managers. Blackstone is the world’s largest, with $1.1 trillion worth of assets under its management, and TPG manages $230 billion.

Hologic is a leading med-tech company in women’s health. It is involved in breast health (mammography and biopsy), cervical cancer screening, infectious disease diagnostics, and surgical and gynecological products.

The deal is expected to close in the first half of 2026, depending on shareholder and regulatory approvals.

Money moving into women’s health

Venture capital, the funding that investors provide to early-stage or growing startups with high potential but also high risk, has been growing in this sector. PitchBook and Deloitte data on U.S. and EU venture funding in women’s health show the number of deals rising from 63 in 2019 to 110 in 2021, 161 in 2023 and 172 in 2024. In 2024, healthtech drew $988M, biopharma $879M, devices $457M and diagnostics and tools $268M.

Even so, only about 2% of VC funding currently goes to women’s health. That shows how under-invested the area is, and how much potential it has for growth.

What to make of it

Overall, this is a great move by Blackstone and TPG. Global awareness about women’s health is growing, with more treatments and more government coverage in areas such as screening, molecular diagnostics and AI imaging.

On return on investment, the buyers will have to be patient. Hologic’s earnings show an 11.5% return on equity, a measure of return on the money invested. Those returns are very modest, but positive overall, and it will take time to turn the company into a very profitable one. COVID hit Hologic very hard, but the company is growing in a positive direction.

Two questions are worth watching. One is how private ownership will affect Hologic’s innovation, capital deployment and further global expansion. The other is whether this deal will spark further M&A in women’s health and foster more growth in the industry.

This article is the text version of a BioAsset slide post. See the original slides on bioasset.info.